Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant TCHP Versus THP in Patients With Human Epidermal Growth Factor Receptor 2-positive Breast Cancer (neoCARHP) : a Randomized, Open-label, Multicenter, Phase III Trial

NCT04858529 is registered in ClinicalTrials.gov with Guangdong Provincial People's Hospital as lead sponsor.

NCT NCT04858529
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04858529 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant TCHP Versus THP in Patients With Human Epidermal Growth Factor Receptor 2-positive Breast Cancer (neoCARHP) : a Randomized, Open-label, Multicenter, Phase III Trial
Lead sponsor
Guangdong Provincial People's Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
April 30, 2021
Completion date
April 30, 2025
Enrollment
774 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neoadjuvant therapies for her2+ breast cancer